Barclays Maintains Overweight on Quest Diagnostics, Raises Price Target to $260
Benzinga Newsdesk 3 weeks ago
Analyst RatingsNewsPrice Target
Barclays analyst Luke Sergott maintains Quest Diagnostics (NYSE:DGX) with a Overweight and raises the price target from $250 to $260.
Barclays analyst Luke Sergott maintains Quest Diagnostics (NYSE:DGX) with a Overweight and raises the price target from $250 to $260.